Skip to content

Microdosing: all studies

Page 39 of 56: studies 381 to 390 of 555, newest first. Back to the microdosing overview

Research

Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway

Neuropsychopharmacology February 13, 2026 Fabrizio Ascone, Valeria Buzzelli, Francesca Mottarlini et al. 2 citations

Fragile X Syndrome (FXS) is the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder (ASD). As a synaptic disorder, FXS involves the loss of Fragile X messenger ribonucleoprotein 1 (FMRP), leading to abnormal dendrite development and immature dendritic spines. Serotonergic signaling, essential for neuronal development and circuit remodeling,...

PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial

Palliative Medicine January 30, 2026 James Downar, Julie Lapenskie, Koby Anderson et al.

Background: Psychological distress is a common problem near the end of life, for which we lack effective, timely and scalable treatments. No previous study has assessed whether microdose psilocybin can improve symptoms in this population. Aim: To determine whether microdose psilocybin is safe, feasible and potentially efficacious in a palliative setting. Design: Open label, single-arm clinical...

DOI: 10.1177/02692163261416269 (opens in new tab) Psilocybin Palliative care Clinical trial Microdose +8

Evaluation of 1cp-LSD for Enhancing Welfare in Shelter Dogs: A Randomized Blind Trial with Ethological Intervention.

Veterinary sciences January 19, 2026 Elisa Hernández-Álvarez, Cristina Canino-Quijada, Sira Roiz et al.

Shelter environments frequently expose dogs to chronic stress and anxiety, which can compromise their welfare and reduce their chances of adoption. Recent interest in psychedelic-assisted approaches has suggested potential therapeutic applications in veterinary behavioral medicine, although empirical evidence remains scarce. This study aimed to evaluate the combined effects of low-dose...

Reward-related neural activity after low doses of LSD in participants with depressed mood.

Journal of Psychopharmacology January 13, 2026 James Glazer, Hanna Molla, Royce Lee et al.

Lysergic acid diethylamide (LSD) has been considered as a potential treatment for depression for over 75 years, but its therapeutic potential has only recently been considered in mainstream psychiatry. Repeated ingestion of low doses of LSD ("microdoses") is thought to reduce depression, but the neurobiology underlying this effect is unknown. We previously reported that low doses of LSD...

Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.

JAMA Network Open January 2, 2026 Gianluca Andri Florineth, Isabell Klima, Anna Laura Boeker et al. 5 citations

Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessions. Quantitative evidence on how this concomitant therapy contributes to treatment outcomes is limited, highlighting the need for a systematic synthesis. To evaluate whether the quantity of psychological therapy is associated with symptom reduction...

Making sense of desperation for treatment in decisions to use psychedelics for depression and anxiety: A qualitative Subreddit study anticipating clinical challenges.

General Hospital Psychiatry 2026 David T. Kryszajtys, Carol Strike, Brian Rush et al. 1 citation

Some individuals interpret persistent depression and anxiety, alongside the exhaustion of standard treatment options, as leading to a desperate need for relief. While desperation may shape how people assess treatment options, its role in psychedelic self-treatment and its relevance for emerging clinical models of psychedelic treatment remain underexplored. We collected discussion threads from...

Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twins.

Frontiers in Psychiatry 2026 Sivert Drange, Jacob Cohen, Sys Stybe Johansen et al. 1 citation

Obsessive-Compulsive Disorder (OCD) can present significant challenges to individuals mental health, characterized by intrusive thoughts and repetitive maladaptive behaviors. Recent research into alternative treatments has highlighted psychedelics, notably psilocybin, for their potential therapeutic benefits in various psychiatric disorders, including OCD. This case study evaluated the impact...

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms

Pharmacological Research December 29, 2025 Martina Colognesi, Daniela Gabbia, Anna Signor et al. 3 citations

The therapeutic potential of low, non-psychedelic doses of psilocybin, a fungal tryptamine alkaloid, was investigated in metabolic disorders including obesity, type 2 diabetes mellitus (T2DM), and liver steatosis. Mice fed a high-fat/high-fructose diet received chronic treatment with psilocybin (0.05 mg/kg) for 12 weeks. Body weight, liver histology, insulin sensitivity, and skeletal muscle...

Psychedelics as Novel Therapeutics for Chronic Pain in Veterinary Medicine: A Hypothesis-Driven Protocol Using Low-Dose 1-Cyclopropionyl-D-lysergic Acid Diethylamide (1cp-LSD) in Canine Osteoarthritis.

Animals : an open access journal from MDPI December 19, 2025 Elisa Hernández-Álvarez, Andrea Acosta-Dacal, Octavio P Luzardo et al. 1 citation

Low-dose psychedelics have shown potential in modulating chronic pain in humans, yet their application in veterinary medicine remains unexplored. This study protocol proposes to investigate the therapeutic potential of low-dose oral administration of 1-cyclopropionyl-D-lysergic acid diethylamide (1cp-LSD), a legal LSD analogue in certain countries, for the management of chronic pain in...

DOI: 10.3390/ani16010003 (opens in new tab) Full text (opens in new tab) 1cp-LSD Analgesic Caregiver expectations Chronic pain +4

Amanita Muscaria and Pantherina – Benefit or Danger? Danger Isoxazole Containing Amanita, Present Situation and Prospects for the Legality of It in Europe

Emerging Trends in Drugs, Addictions, and Health December 1, 2025 E. Alexandrova, M. Vishnevskii

The popularity of the red fly agaric in the past 10 years has led not only to a positive impact on the inhabitants of Europe and Asia, but also to a number of hospitalizations and even deaths. Independent macrodosing and combination with other entheogens is especially dangerous. Based on the available literature, as well as independent field studies on volunteers, as well as police and...

DOI: 10.1016/j.etdah.2025.100191 (opens in new tab) Principle of legality Superpower Law and economics